Schedule 13G ownership disclosure

NOVOCURE LTD ORD SHS

Ordinary Shares, no par value per share · CUSIP: G6674U108

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Capital Master Fund, L.P.

    Shares: 8,530,665.00 · Class: 7.6%

  • Soleus Capital, LLC

    Shares: 8,530,665.00 · Class: 7.6%

  • Soleus Capital Group, LLC

    Shares: 8,530,665.00 · Class: 7.6%

  • Soleus Capital Management, L.P.

    Shares: 8,530,665.00 · Class: 7.6%

  • Soleus GP, LLC

    Shares: 8,530,665.00 · Class: 7.6%

  • Guy Levy

    Shares: 8,530,665.00 · Class: 7.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-26-015652
Form type
SCHEDULE 13G/A
Filer
NovoCure Ltd
CIK
CIK 1645113
Filed
Feb 12, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub